Glioblastoma is the most common and devastating type of malignant brain tumor.
enhanced DNA damage in vitro. The clonogenic assay of U87MG demonstrated the radiosensitizing effect of eribulin. The concomitant eribulin and radiation treatment significantly prolonged the survival of mice harboring intracerebral glioma xenografts compared with eribulin or radiation alone (P < .0001). In addition, maintenance administration of eribulin after the concomitant treatment further controlled brain tumor growth. Aberrant microvasculature was decreased in these tumors. Concomitant treatment with eribulin and radiation followed by maintenance administration of eribulin may serve as a novel therapeutic strategy for glioblastomas.
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| INTRODUCTION
Glioblastoma (GBM) is the most common malignant brain tumor and one of the most devastating cancers in humans. Even with intensive chemoradiotherapy after surgical resection, patients' median overall survival (OS) is <2 years. 1 A series of large-scale genomic studies in the last decade have provided a vast amount of information regarding the genetic alterations in GBM, which may lead to a better understanding of these tumors. [2] [3] [4] It has, however, also been revealed that the extensive molecular heterogeneity in GBM may be responsible for the failure of a number of molecular targeting therapies. [5] [6] [7] A novel therapeutic strategy for GBM is desperately needed.
For a newly diagnosed GBM, a maximum safe surgical resection followed by combined radiation therapy and chemotherapy with temozolomide (TMZ) is the current standard of care. Radiation suppresses the growth of GBM and prolongs the survival of patients with GBM, and, therefore, it is central to the treatment of GBM. 8 Radiosensitization by arresting the cell cycle in M-phase has been shown to increase the efficacy of radiation. A number of previous reports have shown that cells arrested in M-phase by chemotherapy are highly sensitive to DNA damage and that cell death is efficiently induced in some cases, a phenomenon described as mitotic catastrophe. [9] [10] [11] [12] [13] Eribulin methylate (eribulin), a non-taxane inhibitor of microtubule dynamics, has been approved for late-stage and refractory breast cancer, liposarcoma and sarcoma in many countries. The mode of action is reported to be microtubule inhibition-dependent apoptosis and normalization of the tumor microenvironment through vascular remodeling. [14] [15] [16] [17] [18] [19] [20] The distribution of eribulin to the normal brain in mice has been reported to be low, and the clinical benefit of this agent for GBM is considered to be limited. 21, 22 However, recently, we found that eribulin penetrates brain tumor tissues at a high concentration in an intracerebral mouse brain tumor model and suppresses tumor growth, suggesting that eribulin may have activity against GBM in a clinical setting (Takahashi, manuscript submitted).
In fact, consistent with its anti-microtubule activity, eribulin treatment with radiation therapy has been shown to be effective against brain metastasis from breast cancer in several case reports. [23] [24] [25] [26] Because radiation is a part of the standard therapy for newly diagnosed GBM, studying the effect of eribulin as a radiosensitizer has great clinical value.
In this study, we investigated the effect and mechanism of a combined eribulin and radiation treatment on suppressing glioma growth in an intracerebral GBM xenograft model. We showed that the combination induced DNA damage in vitro and prolonged survival in an intracranial xenograft mouse model. In addition, the continued administration of eribulin after radiation prevented tumor recurrence and reduced abnormal angiogenesis. Our results suggest that the concomitant administration of eribulin with radiation may serve as an effective novel treatment strategy for GBM.
| MATERIALS AND METHODS

| Compound and cell lines
Eribulin (Halaven) was purchased from Eisai (Tsukuba, Japan). The eribulin dose per administration for intracranial tumors was 0.5 mg/ kg, which is equivalent to the clinical dose in humans. For subcutaneous tumors, 0.05 or 0.5 mg/kg was used (see below). Injecting these doses 3 times per week for a long period of time was found to be safe and tolerable in a preliminary experiment even with whole brain radiation therapy (data not shown 
| Clonogenic assay
The clonogenic assay was performed as previously described with some modifications. 30 Briefly, cell lines were seeded in 25-cm 2 
| Immunohistochemistry
Resected mouse brains were sliced and fixed in 10% buffered forma- Quantification of the CD34-positive vascular area was performed using ImageJ software. 31 MVA was calculated as the average of 5 vascular hot spots (500 9 500 lm 2 in each spot) chosen in each sample.
| Flow cytometry
Flow cytometry analysis was performed as previously described. 
| Quantification of cell death rate
The rate of cell death induction was assayed by co-staining of treated cells with propidium iodide (PI, Thermo Fisher Scientific) and DAPI (Thermo Fisher Scientific). Fluorescence images of PI and DAPI were acquired using an Olympus CKX53 microscope, and the num- 
| Animals and tumor models
Glioma cell xenografts were generated as described previously. Laboratories Japan). The mice were subjected to irradiation (2) (3) (4) restricted to the left leg or head while the rest of the body was protected by a lead shield. All treatments were performed when the mice were 5-7 weeks old. Eribulin or saline was intraperitoneally injected.
The mouse weights and tumor sizes were measured at least twice a week before starting treatment, and tumor volume was calculated using the long axis and minor axis as described previously. 33 All mice were irradiated under anesthesia. All animal studies were approved by the Animal Experimental Committee of the National Cancer Center and were performed in accordance with the Guidelines for Animal Experiments of the National Cancer Center, which concur with the ethical guidelines for experimental animals in Japan.
| Irradiation
Cells were exposed to c-irradiation using a Gamma-Cell Exactor 40
(with 137-Cs) at approximately 1 Gy/min at the National Cancer Center Research Institute in Japan. Mice were irradiated by X-rays using a CP-160 (Acrobio) at approximately 0.33 Gy/min. Mice were stabilized in irradiation containers during irradiation of the left leg.
The radiation dose for the mice was set to 4 Gy each time to simulate the clinical whole brain radiation dose of 2-4 Gy. The Student t test was performed for cell death rate. P-values below .05 were considered significant. A log-lank test was performed for the Kaplan-Meier survival curve. All analyses were performed using GraphPad Prism 5 software.
3 | RESULTS
| Eribulin arrests the cell cycle of glioma cell lines, induces DNA damage in mitotic phase when combined with radiation, and shows a sensitizing interaction in vitro
We first investigated the effect of eribulin on inhibiting microtubule dynamics in the U87MG glioma cell line using flow cytometry. As previously reported, 18 we confirmed that eribulin induced cell cycle arrest in G2/M-phase ( Figure 1A ). The phosphorylated form of histone H3 was increased upon exposure to eribulin in a dose-dependent manner with or without radiation ( Figure pase-dependent cell death was significantly reduced (P < .01, t test). Thus, the increased cell death caused by addition of radiation to eribulin appeared to include a caspase-independent mechanism.
To further validate the radiosensitizing effect of eribulin, we performed a clonogenic assay using U87MG cells. The adjusted killing curve revealed a radio-sensitizing effect of eribulin ( Figure S1D ).
Taken together, these results suggested that the combination of eribulin and radiation may be effective against GBM.
| Combined effects of eribulin and radiation in vivo
The radiosensitizing effect of eribulin was then examined in vivo by treating xenografted mice with either eribulin or radiation alone or both in combination. For the intracerebral glioblastoma xenograft model, 0.5 mg/kg eribulin per administration, which is equivalent to the clinical dose for humans, was intraperitoneally administered 6 times in 12 days (Figure 2A ). The local radiation dose was set to 3 9 4 Gy, and the body of the mice was protected from radiation.
For combined treatment, the xenografted tumors were irradiated 24 hours after eribulin injection, as was done in vitro. The results
showed that radiation alone did not have a survival benefit over the untreated control, whereas 0.5 mg/kg eribulin significantly prolonged the survival of mice harboring intracerebral U87MG xenografts (Figure 2B) . When radiation and eribulin were concomitantly given, however, radiation significantly prolonged the survival of mice with intracerebral tumors compared to that in mice treated with either radiation or eribulin alone. These data supported the idea that eribulin has a radiosensitizing effect on mouse U87MG brain xenografts.
For the subcutaneous xenograft model, the radiosensitization 
| Survival benefits of the maintenance administration of eribulin after the combined therapy
We further determined whether the continued administration of eribulin produced a more sustained effect on the inhibition of microtubule dynamics and suppression of tumor growth. To validate this hypothesis, we performed another set of experiments using U87MG brain xenografted mice (Figure 3 ). In one set of animals (n = 6), eribulin (0.5 mg/kg) was given intraperitoneally 3 times/week continually until the mice had deteriorated and were euthanized. In another set (n = 7), 4 Gy radiation was given 3 times in the first week alone, and eribulin (0.5 mg/kg, 3 times/week) was given continually until the mice had deteriorated (Figure 4 ). The survival rates of the mice continually treated with eribulin with or without radiation were compared with those of untreated U87MG brain xenografted mice (n = 3) or those treated with radiation alone (n = 3).
The results showed that while the animals continually treated with eribulin alone survived significantly longer than the untreated controls or those treated with radiation alone, those treated with radiation and continual eribulin lived significantly longer than those treated with eribulin alone; only 2 mice died as a result of the brain tumor 80 days after the initiation of the treatment ( Figure 3B ).
These results further confirmed the synergistic effect of eribulin and radiation, which suggests that the cytostatic effect of the long-term administration of 0.5 mg/kg eribulin after concomitant therapy with radiation may lead to sustained tumor control.
| Effects of eribulin on tumor vascular area after radiation in intracranial xenograft models
It is widely known that abnormal angiogenesis occurs after tumor irradiation and that it may contribute to tumor recurrence. 36, 37 Since the suppressive effect of eribulin on vascular remodeling was recently reported, 19, 20 we determined whether eribulin administration neutralized the radiation-induced abnormal vascularization in tumors. The treatment schedule was optimized to evaluate vascular remodeling, 20 especially to assess the late effects of radiation (Figure 4A) . Figure 4B presents representative histopathological images. 93) . B, A Kaplan-Meier survival curve of mice harboring U87MG intracerebral xenografts treated with eribulin and radiation. There were 9-10 mice in each group. C, Representative H&E-stained histological images of U87MG xenografts at the end of the treatment schedule Although the difference was not statistically significant, the irradiated xenografts tended to have a higher MVA compared to that of the control group. When eribulin was given concomitantly with or after irradiation, however, MVA was significantly higher in the eribulin +/after irradiated group compared with that in the radiation alone group ( Figure 4C ). These results suggested that eribulin may normalize the radiation-induced aberrant vascular microenvironment.
| DISCUSSION
In the present study, we demonstrated that eribulin exerted a synergistic effect with radiation to suppress the growth of glioma cells (Figure 1) . Moreover, the concomitant eribulin and radiation treatment significantly prolonged the survival of mice with intracerebral xenografts of gliomas compared to that of mice treated with eribulin or radiation monotherapy (Figure 2) . We previously showed that intravenously administered eribulin reached xenografted mouse brain tumor tissues at a high concentration comparable to that in plasma, and that a clinically equivalent dose of eribulin significantly prolonged survival of mice intracerebrally xenografted with U87MG or several other patient-derived serum-free cultured glioma cells (Takahashi, manuscript submitted). Together with these data, our results strongly suggest that the combined eribulin and radiation treatment may serve as an attractive, novel therapeutic strategy for newly diagnosed GBM. The potential mechanisms by which eribulin and radiation cooperate to suppress glioma growth are discussed below ( Figure 5 ).
First, we demonstrated that DNA damage was induced by the combined eribulin and radiation treatment. It is plausible that radiation-induced DNA damage was enhanced by cell cycle arrest, most likely at M-phase, by eribulin. We showed that the combination of eribulin and radiation increased cell death in glioma cells through a caspase-independent mechanism. We further validated the radiosensitizing effect of eribulin. The combined eribulin and radiation treatment showed increased DNA damage and death rates in U87MG cells, suggesting the synergistic effect of the combined treatment ( Figure S1D ). It should be noted that the dosage of eribulin was reduced to 0.05 nmol/L in this assay, which was below the level at which eribulin induced cell cycle arrest, because eribulin itself has a strong colony formation-inhibiting activity in glioma cell lines. We hypothesize that the mechanism for this effect may be at least in part due to inhibition of microtubule dynamics, which may enhance the cytocidal effect of radiation. In the in vivo experiments, eribulin alone significantly increased the number of "abnormal mitotic cells," suggesting that eribulin may have an inhibitory effect on microtubule dynamics ( Figure 2C, Figure S4 ). The fact that these cells were not seen in the tumor tissues treated with the combination of eribulin and radiation therapy suggests the possibility that they were mostly On the other hand, radiation itself also induces hypoxia. [36] [37] [38] Lesions in a tumor where abnormal blood vessels develop may be susceptible to hypoxia because of the unstable blood flow ("cycling hypoxia lesion"), possibly activating HIF-1. 37 Radiation could cause the lesion to become reoxygenated as a consequence of effective oxygenated tumor cell death. However, this may also generate reactive oxygen species (ROS) in the oxygenated lesion and stabilize HIF-1, eventually further enhancing angiogenesis to support tumor growth. 36 We showed that the combination of eribulin and radiation It has also been reported that in breast cancer patients, bevacizumab non-responders showed higher degrees of angiogenesis with more severe hypoxia during bevacizumab treatment compared to responders. 39 Oxygen saturation in breast cancers was shown to increase in patients treated with eribulin but not in those treated with bevacizumab. 19 These data suggest that eribulin may also be beneficial to patients with GBM who do not respond to bevacizumab.
Another intriguing finding is that the continual administration of eribulin after concomitant treatment with eribulin and radiation resulted in a more sustained inhibition of tumor growth in intracerebral U87MG xenografts than eribulin alone ( Figure 3B ). It was particularly notable that only a single cycle (4 Gy 93) of irradiation given in the first week, which did not improve the survival of the brain tumor-bearing mice on its own, was sufficient to significantly enhance the life-prolonging effect of eribulin ( Figure 2B ). It is possible that the initial concomitant eribulin and radiation treatment was so effective at killing glioma cells that the maintenance administration of eribulin more efficiently controlled recurrence than eribulin alone. The mechanism of the prolonged cytostatic effect of maintenance eribulin when combined with radiation requires further investigation.
Taken together, we propose a new therapeutic strategy for GBM: a concomitant treatment with eribulin and radiation to 
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